Related references
Note: Only part of the references are listed.Platelet thrombin receptor antagonism and atherothrombosis
Dominick J. Angiolillo et al.
EUROPEAN HEART JOURNAL (2010)
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Shinya Goto et al.
EUROPEAN HEART JOURNAL (2010)
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial
David A. Morrow et al.
AMERICAN HEART JOURNAL (2009)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale
Robert A. Harrington et al.
AMERICAN HEART JOURNAL (2009)
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Richard C. Becker et al.
LANCET (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis
Lisa K. Jennings
THROMBOSIS AND HAEMOSTASIS (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Protease-activated receptors in cardiovascular diseases
Andrew J. Leger et al.
CIRCULATION (2006)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
DL Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Protease-activated receptors in hemostasis, thrombosis and vascular biology
SR Coughlin
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial
SD Wiviott et al.
CIRCULATION (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
MS Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
